Market Analysis and Price Projections for the Drug NDC: 72819-186 (Imatinib Mesylate)
Introduction
Imatinib mesylate, identified by the National Drug Code (NDC) 72819-186, is a prescription drug used primarily in the treatment of certain types of cancer, such as chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Here, we will delve into the market analysis and price projections for this drug.
Market Overview
The pharmaceutical market, particularly the segment involving biopharmaceuticals and biotechnology, is experiencing significant growth. As of 2024, the biopharma market size is estimated to be over $400 billion, with a projected compound annual growth rate (CAGR) of 7.56% between 2024 and 2029[3].
Drug Specifics
- Generic Name: Imatinib Mesylate
- Proprietary Name: imatinib mesylate
- Dosage Form: Tablet
- Route of Administration: Oral
- Active Ingredient Strength: 400 mg/1[1]
Market Demand and Usage
Imatinib mesylate is a critical drug for patients with CML and GIST. The demand for this drug is steady due to its effectiveness in treating these conditions. However, the market demand can be influenced by several factors, including the availability of generic versions and changes in treatment protocols.
Price Trends
The prices of prescription drugs, including imatinib mesylate, have been a subject of concern due to their impact on patient affordability and healthcare costs. Between 2018 and 2023, many prescription drugs experienced significant price increases, ranging from 20% to 55%[2].
Impact of Generic Versions
The introduction of generic versions of imatinib mesylate can significantly affect the market dynamics. Generic drugs are typically priced lower than their branded counterparts, which can lead to a reduction in overall market prices. For instance, the entry of generic imatinib mesylate could reduce the market share of the branded version, leading to lower prices and increased accessibility for patients.
Regulatory and Pricing Negotiations
The Medicare Drug Price Negotiation Program is set to begin in January 2026, which will involve negotiations for the prices of certain high-cost drugs, including some cancer treatments. While imatinib mesylate is not specifically mentioned among the first 10 drugs selected for negotiation, such programs can set precedents for broader price negotiations in the pharmaceutical industry. Negotiations under this program have resulted in discounts ranging from 38% to 79% compared to list prices[2].
Market Projections
- Sales Growth: The overall market for cancer treatments, including targeted therapies like imatinib mesylate, is expected to grow. For example, the non-small cell lung cancer (NSCLC) market, which includes other targeted therapies, is projected to see significant growth driven by premium-priced immunotherapies and targeted therapies[4].
- Price Stability: While the prices of many prescription drugs have increased, the introduction of generic versions and regulatory efforts to control prices could lead to more stable or even reduced prices for imatinib mesylate in the future.
- Competitive Landscape: The market for cancer treatments is highly competitive, with multiple drugs and combinations being used. Imatinib mesylate will need to compete with other targeted therapies and potentially newer treatments that may emerge.
Key Takeaways
- Market Growth: The biopharma and biotech markets are growing rapidly, driven by technological advancements and evolving regulatory frameworks.
- Price Trends: Prescription drug prices, including those for imatinib mesylate, have seen significant increases but may stabilize or decrease due to generic versions and regulatory negotiations.
- Regulatory Impact: Programs like the Medicare Drug Price Negotiation Program can influence pricing across the industry.
- Competitive Landscape: The market for cancer treatments is highly competitive, with imatinib mesylate facing competition from other targeted therapies.
FAQs
Q: What is the primary use of imatinib mesylate?
A: Imatinib mesylate is primarily used in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
Q: How has the price of imatinib mesylate changed over recent years?
A: While specific data for imatinib mesylate is not provided, many prescription drugs have seen price increases ranging from 20% to 55% between 2018 and 2023.
Q: What impact do generic versions have on the market price of imatinib mesylate?
A: Generic versions of imatinib mesylate can significantly reduce the market price by offering a lower-cost alternative to the branded version.
Q: How does the Medicare Drug Price Negotiation Program affect drug prices?
A: The program negotiates prices for certain high-cost drugs, resulting in discounts ranging from 38% to 79% compared to list prices.
Q: What are the projected sales trends for cancer treatments like imatinib mesylate?
A: The market for cancer treatments, including targeted therapies, is expected to grow, driven by premium-priced immunotherapies and other targeted therapies.
Sources
- FDA.report: NDC 72819-186 Oral Tablet imatinib mesylate Drug.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
- Drug Development: NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025.
